

## PRESS RELEASE

### Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

(Oxford, UK and Conshohocken, US, 31 October 2017) Immunocore Limited, the world's leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting. This year's SITC is taking place 8 – 12 November, 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland in USA.

#### Poster Presentation Information:

**Title:** Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials

**Authors:** Richard Carvajal, Takami Sato, Alexander N. Shoushtari, Joseph Sacco, Paul Nathan, Marlana Orloff, Pippa Corrie, Neil Steven, Jeff Evans, Jeffrey Infante, Mario Sznol, Clive Mulatero, Omid Hamid, Leonel Hernandez-Aya, Nicola Little, Cheryl McAlpine, David Krige, Namir J. Hassan, Sanjay Patel, Ann-Marie Hulstine, Christina M. Coughlin, Mark R. Middleton

**Category:** Clinical Trials (Completed)

**Date:** Saturday 11 November 2017

**Time:** 12:30 – 14:00 & 18:30 – 20:00

**Abstract Number:** P208

The details of the clinical trial can be found on [clinicaltrials.gov](http://clinicaltrials.gov).

Furthermore, a poster presenting findings from a study mapping the treatment pathway for patients with metastatic uveal melanoma in England will be presented.

**Title:** Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study

**Authors:** Elisabeth Adams, Chih-Yuan Cheng, Joseph Sacco, Sarah Danson, Pippa Corrie, Paul Nathan, Peter Szlosarek, Joanne Upton, Abolore Amuludun, Toby Toward

**Category:** Best Practices for Improving Cancer Immunotherapy Treatment Administration and Polypharmacy Management

**Date:** Friday 10 November 2017

**Time:** 12:30 – 14:00 & 18:30 – 20:00

**Abstract:** P437

To view the posters, please visit the SITC website at <https://www.sitcancer.org/2017/abstracts/info>

SITC is the world's leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

- Ends -

## For more information, please contact:

### Immunocore

Eva-Lotta Allan, Chief Business Officer

T: +44 (0)1235 438600

E: [info@immunocore.com](mailto:info@immunocore.com)

Follow on Twitter: [@Immunocore](https://twitter.com/Immunocore)

### Consilium Strategic Communications

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: [Immunocore@consilium-comms.com](mailto:Immunocore@consilium-comms.com)

Follow on Twitter: [@ConsiliumHC](https://twitter.com/ConsiliumHC)

## Notes for editors

### About Immunocore

Immunocore is the world's leading T cell receptor (TCR) company, a global biotech striving to change medical practice in the most challenging disease areas. Immunocore is focused on delivering first-in-class biological therapies for patients, deploying its pioneering soluble TCR technology. This new class of TCR-based bi-functional drug with ultra-high affinity for intracellular cancer targets is based on synthetic, soluble TCRs that naturally recognize cells containing disease specific targets and selectively kill them. Unlike most biological treatment modalities, this technology can address both extra and intracellular disease targets. These TCR-based therapeutics can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies. Immunocore's TCR technology has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours, infectious diseases and autoimmune diseases.

Across the oncology pipeline, Immunocore has collaborations with Genentech, GlaxoSmithKline, MedImmune (the biologics division of AstraZeneca) and a co-discovery and co-development partnership with Lilly across a range of solid tumours. Immunocore's wholly-owned lead programme, IMCgp100, is in a pivotal monotherapy trial in patients with metastatic uveal melanoma. This study trial builds on the first ever demonstration of compelling single agent efficacy in a solid, 'cold', low mutation tumour, which is challenging for most currently available immuno-oncology agents to address. The Company has also entered into combination trials with IMCgp100 in metastatic cutaneous melanoma with MedImmune.

Immunocore is headquartered near Oxford, UK, with offices near Philadelphia, US. The Company is privately held by a broad international and private investor base. For more information, please visit [www.immunocore.com](http://www.immunocore.com).

### About IMCgp100

IMCgp100 is a novel bispecific biologic, an ImmTAC<sup>®</sup> which is capable of redirecting T cells against the melanocyte-associated antigen gp100. It has a molecular weight of 77 kilo Dalton (kD). IMCgp100 is

manufactured in *E. coli* and scaled to commercial scale. The drug is administered on a weekly basis. In the first-in-human (FIH) clinical trial (IMCgp100-01), preliminary efficacy of IMCgp100 in advanced uveal and cutaneous melanoma was observed. IMCgp100 is the only novel agent that has initiated pivotal studies in metastatic uveal melanoma. IMCgp100 was granted orphan drug designation by the US Food and Drug Administration in 2016.

In addition to the uveal melanoma study, IMCgp100 is also conducting a clinical combination study with MedImmune's checkpoint inhibitors Imfinzi (durvalumab, anti-PDL-1) and tremelimumab (anti-CTLA-4) in patients with metastatic cutaneous melanoma who no longer respond to anti-PD-1 therapies.

## About Uveal Melanoma

Uveal melanoma is a rare and aggressive form of melanoma which affects the eye with a poor prognosis and no standard of care. Although uveal melanoma is the most common primary intraocular malignancy in adults, representing approximately 3-4% of all melanomas, the diagnosis is rare with approximately 4,000 new patients globally diagnosed per year (1,500 cases/year in US) all stages combined (Chattopadhyay, 2016). Despite aggressive local therapy with surgery and/or radiation therapy, the 5-year survival rate (76%) has not changed in over 30 years (Mahendraraj, 2017) and up to 50% of patients with local disease will develop metastases (Carvajal, 2017; Kujala, 2003). Despite extensive investigation of metastatic uveal melanoma in the clinic, to date no systemic treatment has demonstrated improved survival and no effective therapy has been identified in this disease setting (Carvajal, 2017).

Checkpoint inhibitors and other novel therapies that have transformed the management of cutaneous melanoma, only have limited efficacy in uveal melanoma with an overall response rate (ORR) of only ~5%. The median progressive free survival is no more than 3 months with a median overall survival (OS) ranging from 5 to 10 months. Consequently, there is a critical unmet need for new treatment approaches.

## About ImmTAC® Molecules

Immunocore's best in class proprietary TCR technology is focused on a small protein drug called the ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecule that enables the immune system to recognise and kill cancerous cells. Immunocore's world-leading competitive advantage is its ImmTAC molecules, a new class of drug with ultra-high affinity for intracellular cancer targets, which is based on synthetic, soluble T cell receptors (TCRs) that naturally recognize cells containing disease specific targets and selectively kill them.

ImmTAC molecules can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies. Immunocore's TCR technology has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours and can expand into infectious diseases and autoimmune diseases. In oncology, the molecules have the unique ability to tackle solid "cold" low mutation rate tumours – the majority of tumours.

The technology has an encouraging safety profile and is highly scalable, with a low cost of goods.